AAPL322.63+7.29 (+2.31%) ▲|ABBV252.17+1.26 (+0.50%) ▲|ABT104.35-0.88 (-0.84%) ▼|ACN178.53+2.73 (+1.55%) ▲|ADBE251.73-3.13 (-1.23%) ▼|AMAT458.68-10.18 (-2.17%) ▼|AMD507.81-13.29 (-2.55%) ▼|AMGN383.61-7.66 (-1.96%) ▼|AMT173.00-2.44 (-1.39%) ▼|AMZN252.55+0.15 (+0.06%) ▲|AVGO364.08-0.30 (-0.08%) ▼|AXP321.38-0.42 (-0.13%) ▼|BA207.42+1.00 (+0.48%) ▲|BAC62.47-0.20 (-0.32%) ▼|BKNG176.11+2.68 (+1.54%) ▲|BLK1,073.53+1.50 (+0.14%) ▲|BMY64.03-0.38 (-0.59%) ▼|BNY163.10+0.59 (+0.36%) ▲|BRK-B505.82-0.91 (-0.18%) ▼|C138.16+0.36 (+0.26%) ▲|CAT806.74-8.83 (-1.08%) ▼|CL88.03+0.00 (+0.00%) ▲|CMCSA24.92+0.33 (+1.32%) ▲|COF208.53-2.33 (-1.11%) ▼|COP136.38-0.15 (-0.11%) ▼|COST902.78+0.18 (+0.02%) ▲|CRM245.57+1.41 (+0.58%) ▲|CSCO108.99-0.44 (-0.40%) ▼|CVS95.35-0.03 (-0.03%) ▼|CVX213.24-0.57 (-0.27%) ▼|DE677.60+0.39 (+0.06%) ▲|DHR202.23-2.63 (-1.28%) ▼|DIS104.86+0.68 (+0.65%) ▲|DUK119.41-1.02 (-0.85%) ▼|EMR148.62-1.73 (-1.15%) ▼|FDX312.28+3.09 (+1.00%) ▲|GD353.47+0.80 (+0.23%) ▲|GE325.22-0.20 (-0.06%) ▼|GEV934.42-16.62 (-1.75%) ▼|GILD144.40-1.25 (-0.86%) ▼|GM85.13+1.37 (+1.64%) ▲|GOOG327.56-0.82 (-0.25%) ▼|GOOGL329.97-0.68 (-0.21%) ▼|GS1,025.33-3.45 (-0.34%) ▼|HD307.15-3.30 (-1.06%) ▼|HON203.59-1.34 (-0.65%) ▼|IBM238.05-1.90 (-0.79%) ▼|INTC101.57-4.67 (-4.40%) ▼|INTU315.51+1.57 (+0.50%) ▲|ISRG359.90+6.66 (+1.88%) ▲|JNJ266.69-0.39 (-0.15%) ▼|JPM353.78-0.93 (-0.26%) ▼|KO88.40+0.85 (+0.97%) ▲|LIN461.80-4.86 (-1.04%) ▼|LLY1,128.18+3.97 (+0.35%) ▲|LMT527.14+2.68 (+0.51%) ▲|LOW196.10-2.50 (-1.26%) ▼|LRCX304.33-11.51 (-3.64%) ▼|MA565.40-2.10 (-0.37%) ▼|MCD253.33-0.15 (-0.06%) ▼|MDLZ61.99-0.43 (-0.69%) ▼|MDT91.62-0.28 (-0.30%) ▼|META651.46-2.24 (-0.34%) ▼|MMM162.11-2.30 (-1.40%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.82-2.71 (-1.84%) ▼|MS215.00-0.35 (-0.16%) ▼|MSFT492.59+0.94 (+0.19%) ▲|MU983.74-44.03 (-4.28%) ▼|NEE82.37-0.28 (-0.34%) ▼|NFLX75.97-0.06 (-0.08%) ▼|NKE37.10-0.26 (-0.68%) ▼|NOW134.00+2.89 (+2.20%) ▲|NVDA218.44-5.23 (-2.34%) ▼|ORCL158.89-2.74 (-1.70%) ▼|PEP136.80+0.11 (+0.08%) ▲|PFE27.52-0.26 (-0.94%) ▼|PG142.30-0.34 (-0.24%) ▼|PLTR167.75-1.78 (-1.05%) ▼|PM190.44+4.73 (+2.54%) ▲|QCOM177.91+1.51 (+0.85%) ▲|RTX197.18-0.37 (-0.19%) ▼|SBUX99.98-0.06 (-0.06%) ▼|SCHW107.01+0.47 (+0.44%) ▲|SO87.87-0.47 (-0.53%) ▼|SPG205.70+1.17 (+0.57%) ▲|T25.49+0.34 (+1.33%) ▲|TMO601.57-4.12 (-0.68%) ▼|TMUS176.58-0.76 (-0.43%) ▼|TSLA366.86-0.95 (-0.26%) ▼|TXN260.50-1.09 (-0.42%) ▼|UBER70.98-0.10 (-0.14%) ▼|UNH391.11-1.95 (-0.50%) ▼|UNP285.51+0.77 (+0.27%) ▲|UPS99.80+0.58 (+0.58%) ▲|USB62.06-0.05 (-0.08%) ▼|V366.73-0.66 (-0.18%) ▼|VZ49.93+0.19 (+0.37%) ▲|WFC89.22-0.46 (-0.51%) ▼|WMT105.92+0.09 (+0.08%) ▲|XOM164.76+0.53 (+0.32%) ▲|AAPL322.63+7.29 (+2.31%) ▲|ABBV252.17+1.26 (+0.50%) ▲|ABT104.35-0.88 (-0.84%) ▼|ACN178.53+2.73 (+1.55%) ▲|ADBE251.73-3.13 (-1.23%) ▼|AMAT458.68-10.18 (-2.17%) ▼|AMD507.81-13.29 (-2.55%) ▼|AMGN383.61-7.66 (-1.96%) ▼|AMT173.00-2.44 (-1.39%) ▼|AMZN252.55+0.15 (+0.06%) ▲|AVGO364.08-0.30 (-0.08%) ▼|AXP321.38-0.42 (-0.13%) ▼|BA207.42+1.00 (+0.48%) ▲|BAC62.47-0.20 (-0.32%) ▼|BKNG176.11+2.68 (+1.54%) ▲|BLK1,073.53+1.50 (+0.14%) ▲|BMY64.03-0.38 (-0.59%) ▼|BNY163.10+0.59 (+0.36%) ▲|BRK-B505.82-0.91 (-0.18%) ▼|C138.16+0.36 (+0.26%) ▲|CAT806.74-8.83 (-1.08%) ▼|CL88.03+0.00 (+0.00%) ▲|CMCSA24.92+0.33 (+1.32%) ▲|COF208.53-2.33 (-1.11%) ▼|COP136.38-0.15 (-0.11%) ▼|COST902.78+0.18 (+0.02%) ▲|CRM245.57+1.41 (+0.58%) ▲|CSCO108.99-0.44 (-0.40%) ▼|CVS95.35-0.03 (-0.03%) ▼|CVX213.24-0.57 (-0.27%) ▼|DE677.60+0.39 (+0.06%) ▲|DHR202.23-2.63 (-1.28%) ▼|DIS104.86+0.68 (+0.65%) ▲|DUK119.41-1.02 (-0.85%) ▼|EMR148.62-1.73 (-1.15%) ▼|FDX312.28+3.09 (+1.00%) ▲|GD353.47+0.80 (+0.23%) ▲|GE325.22-0.20 (-0.06%) ▼|GEV934.42-16.62 (-1.75%) ▼|GILD144.40-1.25 (-0.86%) ▼|GM85.13+1.37 (+1.64%) ▲|GOOG327.56-0.82 (-0.25%) ▼|GOOGL329.97-0.68 (-0.21%) ▼|GS1,025.33-3.45 (-0.34%) ▼|HD307.15-3.30 (-1.06%) ▼|HON203.59-1.34 (-0.65%) ▼|IBM238.05-1.90 (-0.79%) ▼|INTC101.57-4.67 (-4.40%) ▼|INTU315.51+1.57 (+0.50%) ▲|ISRG359.90+6.66 (+1.88%) ▲|JNJ266.69-0.39 (-0.15%) ▼|JPM353.78-0.93 (-0.26%) ▼|KO88.40+0.85 (+0.97%) ▲|LIN461.80-4.86 (-1.04%) ▼|LLY1,128.18+3.97 (+0.35%) ▲|LMT527.14+2.68 (+0.51%) ▲|LOW196.10-2.50 (-1.26%) ▼|LRCX304.33-11.51 (-3.64%) ▼|MA565.40-2.10 (-0.37%) ▼|MCD253.33-0.15 (-0.06%) ▼|MDLZ61.99-0.43 (-0.69%) ▼|MDT91.62-0.28 (-0.30%) ▼|META651.46-2.24 (-0.34%) ▼|MMM162.11-2.30 (-1.40%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.82-2.71 (-1.84%) ▼|MS215.00-0.35 (-0.16%) ▼|MSFT492.59+0.94 (+0.19%) ▲|MU983.74-44.03 (-4.28%) ▼|NEE82.37-0.28 (-0.34%) ▼|NFLX75.97-0.06 (-0.08%) ▼|NKE37.10-0.26 (-0.68%) ▼|NOW134.00+2.89 (+2.20%) ▲|NVDA218.44-5.23 (-2.34%) ▼|ORCL158.89-2.74 (-1.70%) ▼|PEP136.80+0.11 (+0.08%) ▲|PFE27.52-0.26 (-0.94%) ▼|PG142.30-0.34 (-0.24%) ▼|PLTR167.75-1.78 (-1.05%) ▼|PM190.44+4.73 (+2.54%) ▲|QCOM177.91+1.51 (+0.85%) ▲|RTX197.18-0.37 (-0.19%) ▼|SBUX99.98-0.06 (-0.06%) ▼|SCHW107.01+0.47 (+0.44%) ▲|SO87.87-0.47 (-0.53%) ▼|SPG205.70+1.17 (+0.57%) ▲|T25.49+0.34 (+1.33%) ▲|TMO601.57-4.12 (-0.68%) ▼|TMUS176.58-0.76 (-0.43%) ▼|TSLA366.86-0.95 (-0.26%) ▼|TXN260.50-1.09 (-0.42%) ▼|UBER70.98-0.10 (-0.14%) ▼|UNH391.11-1.95 (-0.50%) ▼|UNP285.51+0.77 (+0.27%) ▲|UPS99.80+0.58 (+0.58%) ▲|USB62.06-0.05 (-0.08%) ▼|V366.73-0.66 (-0.18%) ▼|VZ49.93+0.19 (+0.37%) ▲|WFC89.22-0.46 (-0.51%) ▼|WMT105.92+0.09 (+0.08%) ▲|XOM164.76+0.53 (+0.32%) ▲|
27.5 C
New York
Thursday, September 10, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis

– Nuvisertib (TP-3654), an oral investigational highly selective PIM-1 kinase inhibitor, is being evaluated in patients with relapsed or refractory myelofibrosis (MF) – MARLBOROUGH, Mass.,...

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer’s Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-Aβ protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.

The Pankey Institute’s Annual Symposium to be Held September 18-20, 2025 in Palm Beach, Florida

This Year's Theme, "Harmony in Interdisciplinary Care: Blending Expertise," Celebrates True Collaboration in Patient-Centered Dentistry KEY BISCAYNE, Fla., July 30, 2025 /PRNewswire/ -- The Pankey...

OncoHost Named Top Precision Oncology Solution for 2025

BINYAMINA, Israel and CARY, N.C., July 30, 2025 /PRNewswire/ -- OncoHost, a leader in precision oncology leveraging proteomics and AI to personalize cancer care, today...

Subtle Medical Among First to Achieve ISO/IEC 42001:2023 Certification for AI Management

The certification reinforces the company's leadership in AI safety, efficacy, and ethical governance. MENLO PARK, Calif., July 30, 2025 /PRNewswire/ -- Subtle Medical, a global...

NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement.

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

COTA partners with LCP Health Analytics to advance the use of US RWD to support HTA decision making internationally

US + UK Data to Address Key Evidence Gaps in Access to Medicines NEW YORK, July 30, 2025 /PRNewswire/ -- LCP Health Analytics is partnering...

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: 

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

HIMSS partners with WHX Tech to advance digital health transformation in the Middle East

DUBAI, UAE, July 30, 2025 /PRNewswire/ -- The Healthcare Information and Management Systems Society (HIMSS) will deliver world-class content, professional development and roadmaps for digital health...

AltaPointe Health Expands Children’s Outpatient Services with New Mobile County Location

MOBILE, Ala., July 29, 2025 /PRNewswire/ -- AltaPointe Health is excited to announce the opening of its newest children's outpatient clinic located at 4211...

Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis Clinics

CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging SystemThe VxWave Ultrasound Imaging System potentially provides important insights...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers